E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
B-cell acute lymphoblastic leukemia (B-ALL), which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | hlgt |
E.1.2 | Classification code | 10036523 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the safety of repeat doses of intravenous (IV) infusion of forodesine in patients with B-ALL, which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma. |
|
E.2.2 | Secondary objectives of the trial |
• To describe the steady-state pharmacokinetics (PK) of forodesine following repeat administration • To evaluate the pharmacodynamic (PD) effects of forodesine on plasma levels of 2' deoxyguanosine (dGuo) and red blood cell (RBC) purine nucleoside phosphorylase (PNP) activity and to correlate levels with efficacy parameters • To determine the efficacy of repeat doses of IV forodesine as evidenced by peripheral blood evaluations and bone-marrow evaluation • To evaluate the maintenance of response and safety of forodesine with extended treatment
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
• Documented B-cell acute lymphoblastic leukemia (B-ALL) • Must have failed at least 1 treatment regimen for B-ALL • Performance status of ≤2 by Eastern Cooperative Oncology Group (ECOG) criteria • Age 18 years or older • Life expectancy of at least 3 months • Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase [ALT] not >3 times upper limits of normal [ULN]) • Adequate kidney function (calculated creatinine clearance >40 mL/min) • Negative serum or urine pregnancy test within 2 to 7 days prior to the start of study treatment in females of childbearing potential. • Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study in such a manner that the risk of pregnancy is minimized • Signed informed consent form (ICF) prior to start of any study-specific procedures
|
|
E.4 | Principal exclusion criteria |
• Active serious infection not controlled by oral or intravenous antibiotics • Treatment with any investigational antileukemic agent or chemotherapy agent in the last 7 days prior to study entry and lack of full recovery from side effects due to prior therapy independent of when that therapy was given • Rapidly progressive disease with compromised organ function judged to be life threatening by the Investigator • Patients with clinical evidence of active central nervous system (CNS) disease • Concurrent treatment with other anticancer agents • Pregnant and/or lactating female • Patients with known human immunodeficiency virus (HIV) infection • Patients with known active hepatitis B and/or hepatitis C infection • Hypersensitive or intolerant to any component of the study drug formulation
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: Reported adverse events presented by system organ class, preferred term, relationship to study medication and severity. Efficacy: Proportion of patients responding at Day 28. A responder is defined as a patient with either complete response, partial response or complete response in the absence of total platelet recovery. Responses to be confirmed by bone marrow evaluations. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Pharmacokinetic and safety |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be following the recruitment of 20 evaluable patients and the closure of the database containing the data. It is possible that the database will be closed for analysis of the primary and secondary endpoints whilst some patients may still be receiving forodesine hydrochloride under the compassionate use arm of the study. Length of time to receive forodesine hydrochloride under compassionate use is not limited. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |